Therapy-related cardiac risk in childhood cancer survivors: An analysis of the childhood cancer survivor study

Journal of Clinical Oncology

Volumn 37, Issue 13, 2019, Pages 1090-1101

  Bates, James E ^a   Howell, Rebecca M ^b   Liu, Qi ^c   Yasui, Yutaka ^d   Mulrooney, Daniel A ^d   Dhakal, Sughosh ^e   Smith, Susan A ^b   Leisenring, Wendy M ^f   Indelicato, Daniel J ^a   Gibson, Todd M ^d   Armstrong, Gregory T ^d   Oeffinger, Kevin C ^g   Constine, Louis S ^e  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER SURVIVOR; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART VOLUME; HODGKIN DISEASE; HUMAN; LEUKEMIA; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; CANADA; CANCER SURVIVOR; CLINICAL TRIAL; HEART; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PRESCHOOL CHILD; RADIATION RESPONSE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CANADA; CANCER SURVIVORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEART; HEART DISEASES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 85065307804     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.01764     Document Type: Article

References (33)

1. Armstrong GT, Chen Y, Yasui Y, et al: Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med 374:833-842, 2016
2. Armstrong GT, Oeffinger KC, Chen Y, et al: Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31: 3673-3680, 2013
3. van der Pal HJ, van Dalen EC, van Delden E, et al: High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30:1429-1437, 2012
4. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339(dec08 1):b4606, 2009
5. Adams MJ, Lipshultz SE: Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatr Blood Cancer 44:600-606, 2005
6. Lipshultz SE, Adams MJ, Colan SD, et al: Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions-A scientific statement from the American Heart Association. Circulation 128:1927-1995, 2013 [Erratum: Circulation 128:e394, 2013]
7. Haddy N, Diallo S, El-Fayech C, et al: Cardiac diseases following childhood cancer treatment: Cohort study. Circulation 133:31-38, 2016
8. Armenian SH, Hudson MM, Mulder RL, et al: Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123-e136, 2015
9. Taunk NK, Haffty BG, Kostis JB, et al: Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms. Front Oncol 5:39, 2015
10. Krasin MJ, Constine LS, Friedman DL, et al: Radiation-related treatment effects across the age spectrum: Differences and similarities or what the old and young can learn from each other. Semin Radiat Oncol 20:21-29, 2010
11. Paulino AC, Constine LS, Rubin P, et al: Normal tissue development, homeostasis, senescence, and the sensitivity to radiation injury across the age spectrum. Semin Radiat Oncol 20:12-20, 2010
12. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
13. van Dalen EC, van der Pal HJH, Kok WEM, et al: Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 42:3191-3198, 2006
14. Hoppe BS, Flampouri S, Su Z, et al: Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84:449-455, 2012
15. Kalapurakal JA, Zhang Y, Kepka A, et al: Cardiac-sparing whole lung IMRT in children with lung metastasis. Int J Radiat Oncol Biol Phys 85:761-767, 2013
16. Zhang R, Howell RM, Taddei PJ, et al: A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. Radiother Oncol 113:84-88, 2014
17. Zhou R, Ng A, Constine LS, et al: A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the Childhood Cancer Survivor Study and recent Children's Oncology Group trials. Int J Radiat Oncol Biol Phys 95:707-711, 2016
18. Leisenring WM, Mertens AC, Armstrong GT, et al: Pediatric cancer survivorship research: Experience of the Childhood Cancer Survivor Study. J Clin Oncol 27: 2319-2327, 2009
19. Robison LL, Armstrong GT, Boice JD, et al: The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27:2308-2318, 2009
20. Robison LL, Mertens AC, Boice JD, et al: Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol 38:229-239, 2002
21. Stovall M, Weathers R, Kasper C, et al: Dose reconstruction for therapeutic and diagnostic radiation exposures: Use in epidemiological studies. Radiat Res 166: 141-157, 2006
22. Feijen EA, Leisenring WM, Stratton KL, et al: Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. J Clin Oncol 33:3774-3780, 2015
23. Anderson SE, Must A: Interpreting the continued decline in the average age at menarche: Results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr 147:753-760, 2005
24. Childhood Cancer Survivor Study: Questionnaires. https://ccss.stjude.org/tools-and-documents/questionnaires.html
25. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. https://ctep.cancer.gov/protocoldevelopment/ electronicapplications/ctc.htm
26. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
27. Gibson TM, Mostoufi-Moab S, Stratton KL, et al: Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: A report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 19:1590-1601, 2018
28. Lipshultz SE, Cochran TR, Franco VI, et al: Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol 10:697-710, 2013
29. Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961, 2010
30. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
31. Khawaja FJ, Rihal CS, Lennon RJ, et al: Temporal trends (over 30 years), clinical characteristics, outcomes, and gender in patients #50 years of age having percutaneous coronary intervention. Am J Cardiol 107:668-674, 2011
32. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 129:S49-S73, 2014 (suppl 2) [Erratum: Circulation 129:S74-S75, 2014 (suppl 2)]
33. Liu Q, Leisenring WM, Ness KK, et al: Racial/ethnic differences in adverse outcomes among childhood cancer survivors: The Childhood Cancer Survivor Study. J Clin Oncol 34:1634-1643, 2016